DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Silver Spring MD 20993

NDA 20636/S-39
NDA 20933/S-30

SUPPLEMENT APPROVAL

Boehringer-Ingelheim Pharmaceuticals, Inc.
Attention: Wendy Bischof
Manager, Drug Regulatory Affairs
900 Ridgefield, CT 06877-0368

Dear Ms. Bischof:

Please refer to your Supplemental New Drug Applications (sNDA) dated May 13, 2011, received May 13, 2011, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for VIRAMUNE® (nevirapine), 200 mg tablets and 50 mg/5 mL oral suspension.


This “Changes Being Effected” supplemental new drug application was submitted to add decreased serum phosphorus to the Postmarketing Experience section of the package insert, based on a retrospective, post-hoc analysis from three recent clinical trials, 1100.1470 (ARTEN), 1100.1512 (NEWART) and 1100.1486 (VERxVE).

We have completed our review of these supplemental applications, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for package insert and Medication Guide), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible from publicly available labeling repositories.

Reference ID: 3042457
Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705-1266

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at http://www.fda.gov/opacom/morechoices/fdaforms/eder.html; instructions are provided on page 2 of the form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and Communications (DDMAC), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Myung-Joo Patricia Hong, Regulatory Project Manager, at (301) 796-0807.

Sincerely,

{See appended electronic signature page}

Kendall Marcus, M.D.
Deputy Director of Safety
Division of Antiviral Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research
ENCLOSURE:
   Content of Labeling
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

KENDALL A MARCUS
11/09/2011